TgAAC94 gene therapy vector ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
| 271 | Ankylosing spondylitis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00617032 (ClinicalTrials.gov) | February 2004 | 5/2/2008 | Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94 | A Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis | Rheumatoid Arthritis | Genetic: tgAAC94 gene therapy vector;Genetic: tgAAC94 placebo | Targeted Genetics Corporation | NULL | Completed | 18 Years | N/A | Both | 15 | Phase 1 | United States;Canada |
271. Ankylosing spondylitis
Clinical trials : 574 / Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00126724 (ClinicalTrials.gov) | August 2005 | 2/8/2005 | Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects | A Phase I/II Study of Repeat Intra-articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-alpha Antagonists | Arthritis, Rheumatoid;Arthritis, Psoriatic;Ankylosing Spondylitis | Genetic: tgAAC94 gene therapy vector;Genetic: tgAAC94 placebo | Targeted Genetics Corporation | NULL | Completed | 18 Years | 75 Years | Both | 120 | Phase 1/Phase 2 | United States |